Lineage Cell Therapeutics Inc
$ 1.74
3.57%
04 Dec - close price
- Market Cap 400,770,000 USD
- Current Price $ 1.74
- High / Low $ 1.75 / 1.62
- Stock P/E N/A
- Book Value 0.10
- EPS -0.29
- Next Earning Report 2026-03-05
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.14 %
- ROE -1.58 %
- 52 Week High 2.09
- 52 Week Low 0.36
About
Lineage Cell Therapeutics, Inc. is a forward-looking clinical-stage biotechnology firm based in Carlsbad, California, specializing in the development and commercialization of innovative cell-based therapies for degenerative diseases. With a strong emphasis on regenerative medicine, the company harnesses proprietary technologies to address significant unmet medical needs globally. Lineage boasts a robust and diverse pipeline supported by strategic collaborations, positioning it for substantial growth as it advances its clinical candidates. This unique focus on regenerative therapeutics makes Lineage an attractive investment opportunity for institutional investors seeking to capitalize on advancements in the biotech sector.
Analyst Target Price
$4.17
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-06 | 2025-08-12 | 2025-05-07 | 2025-03-05 | 2024-11-07 | 2024-08-08 | 2024-05-09 | 2024-03-07 | 2023-11-09 | 2023-08-10 | 2023-05-11 | 2023-03-09 |
| Reported EPS | -0.13 | -0.13 | -0.02 | -0.01 | -0.02 | -0.03 | -0.04 | -0.03 | -0.04 | -0.03 | -0.03 | -0.03 |
| Estimated EPS | -0.02 | -0.03 | -0.028 | -0.03 | -0.04 | -0.05 | -0.04 | -0.04 | -0.04 | -0.04 | -0.04 | -0.04 |
| Surprise | -0.11 | -0.1 | 0.008 | 0.02 | 0.02 | 0.02 | 0 | 0.01 | 0 | 0.01 | 0.01 | 0.01 |
| Surprise Percentage | -550% | -333.3333% | 28.5714% | 66.6667% | 50% | 40% | 0% | 25% | 0% | 25% | 25% | 25% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-03-05 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | -0.0257 |
| Currency | USD |
Previous Dividend Records
| Jan 1970 | |
|---|---|
| Payment Date | None |
| Amount | $0.3125 |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: LCTX
2025-11-02 00:00:00
Lineage Cell Therapeutics has announced a three-year research collaboration with William Demant Invest (WDI) to advance the preclinical development of ReSonance (ANP1) for hearing loss. WDI will contribute up to $12 million for development costs, with joint efforts from Lineage and Eriksholm Research Centre scientists. This partnership aims to integrate expertise in hearing loss research and cell transplant technology to develop a differentiated cell therapy for auditory neuropathy ahead of potential clinical trials.
2025-10-16 15:45:41
Lineage Cell Therapeutics' CEO, Brian Culley, will be attending the American Academy of Ophthalmology (AAO) Annual Meeting in Orlando, Florida, from October 18-21. This attendance signals the company's commitment to staying current with ophthalmological advancements. The AAO meeting is a key event for experts and industry leaders in the field.
2025-09-02 12:00:00
Lineage Cell Therapeutics announced CEO Brian M. Culley will present at the H.C. Wainwright 27th Annual Global Investment Conference on September 8, 2025, and Baird's 2025 Global Healthcare Conference on September 9, 2025. Investors are invited to schedule in-person meetings with the management team. A replay of the H.C. Wainwright presentation will be available on the company's website.
2025-06-23 07:33:00
Lineage Cell Therapeutics Inc. stock held steady after H.C. Wainwright reiterated its Buy rating and $9.00 price target, driven by positive 3-year clinical data presented by its partner Roche/Genentech for their cell therapy targeting geographic atrophy. The data showed continued efficacy with a single infusion, differentiating it from current treatments. Lineage also announced a change in its auditing firm and a successful cGMP cell banking production run for scalable cell-based product candidates.
2025-05-13 00:00:00
Lineage Cell Therapeutics (NYSE American and TASE: LCTX) reported its first-quarter 2025 financial results and provided a business update, highlighting its growing confidence in OpRegen's potential for treating geographic atrophy secondary to AMD. The company announced the initiation of a clinical study for its OPC1 delivery device for spinal cord injury and the upcoming 3rd Annual SCI Investor Symposium. Financially, Lineage reported $1.5 million in revenue and a net loss of $4.1 million for the quarter, with cash reserves projected to support operations into Q1 2027.
2025-01-01 00:00:00
Lineage Cell Therapeutics issued a letter to its stockholders highlighting recent achievements and the company's outlook for 2025, emphasizing its position as a "cell transplant company" rather than a "stem cell" company. The letter discusses Lineage's financing strategy, manufacturing capabilities, and long-term goals, including advancing its OpRegen program with Roche and Genentech, and its pipeline of neurological cell transplant candidates. The company also detailed its intention to be the first to demonstrate multiplicative scalable manufacturing for allogeneic cell therapies.
